


Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer Algorithm



Notes. *Data from the primary analysis of CheckMate 648 supports Recommendation 1.3 in patients with ESCC and PD-L1 TPS ≥1%. Additional exploratory analyses from CheckMate 648 found that 91% of patients across three study arms had PD-L1 CPS ≥1, therefore, CPS ≥1 may be used as a threshold for treatment decision-making if TPS is not available.

Abbreviations. CPS, combined positive score; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; PD-L1, programmed death-ligand 1; TPS, tumor proportion score

This algorithm is derived from recommendations in *Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline*. This is a tool based on an ASCO Guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the guideline and this tool are voluntary.